Symbols / CYCN
CYCN Chart
About
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.02M |
| Enterprise Value | 456.20K | Income | -2.20M | Sales | 2.85M |
| Book/sh | 2.58 | Cash/sh | 1.20 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1 | IPO | — |
| P/E | — | Forward P/E | -1.01 | PEG | — |
| P/S | 1.76 | P/B | 0.51 | P/C | — |
| EV/EBITDA | — | EV/Sales | 0.16 | Quick Ratio | 5.32 |
| Current Ratio | 5.78 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.70 | EPS next Y | -1.31 | EPS Growth | — |
| Revenue Growth | 3.51% | Earnings | 2022-11-03 17:00 | ROA | -23.51% |
| ROE | -24.80% | ROIC | — | Gross Margin | 92.64% |
| Oper. Margin | -114.97% | Profit Margin | -77.02% | Shs Outstand | 3.81M |
| Shs Float | 3.07M | Short Float | 5.20% | Short Ratio | 0.04 |
| Short Interest | — | 52W High | 3.79 | 52W Low | 1.03 |
| Beta | 0.95 | Avg Volume | 1.54M | Volume | 25.50K |
| Target Price | $8.00 | Recom | Strong_buy | Prev Close | $1.32 |
| Price | $1.32 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$1.32
Latest analyst target
3. DCF / Fair value
$-6.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.32
Low
$8.00
High
$8.00
Mean
$8.00
- Anesthesia-based therapy for treatment-resistant depression enters Phase 2 - Stock Titan ue, 17 Feb 2026 12
- Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next - TechStock² ue, 06 Jan 2026 08
- Insiders Rewarded With US$55k Addition To Investment As Cyclerion Therapeutics Stock Hits US$7.6m - simplywall.st ue, 23 Sep 2025 07
- Why Is Cyclerion Stock Surging In Pre-market Trade? - Nasdaq Wed, 24 Sep 2025 07
- Cyclerion stock soars after MIT licensing deal to relaunch company - Investing.com ue, 23 Sep 2025 07
- Insider Stock Buying Reaches US$525.0k On Cyclerion Therapeutics - Yahoo Finance ue, 11 Nov 2025 08
- Why Did Cyclerion Therapeutics Stock Surge Nearly 50% After-Hours Today? - Stocktwits Wed, 24 Sep 2025 03
- Exciting Surge in Cyclerion: What’s Next? - StocksToTrade ue, 06 Jan 2026 08
- Cyclerion Gains FDA Support for CYC-126 Depression Study - TipRanks ue, 17 Feb 2026 12
- Cyclerion Therapeutics Announces Strategic Relaunch and Licensing Agreement with MIT to Address Treatment-Resistant Depression - Quiver Quantitative ue, 23 Sep 2025 07
- Morning Market Movers: CYCN, AZI, AEVA, OS See Big Swings - RTTNews ue, 06 Jan 2026 08
- Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2% - Intellectia AI ue, 06 Jan 2026 08
- Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket - Benzinga ue, 06 Jan 2026 08
- Cyclerion Therapeutics stock soars after strategic Medsteer collaboration By Investing.com - Investing.com Nigeria Mon, 05 Jan 2026 08
- Cyclerion Expands Partnership With Medsteer; Plans Phase 2 Trial Of CYC-126 In 2H 2026; Stock Up - Nasdaq ue, 06 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 181818 | 500000 | — | Stock Award(Grant) at price 2.75 per share. | HECHT PETER M | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-25 00:00:00 | D |
| 1 | 9090 | 24998 | — | Stock Award(Grant) at price 2.75 per share. | HIGGINS MICHAEL J | Director | — | 2025-03-25 00:00:00 | D |
| 2 | 357880 | 555108 | — | Sale at price 1.55 per share. | SLATE PATH CAPITAL LP | Beneficial Owner of more than 10% of a Class of Security | — | 2024-11-21 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -3.63M | -6.34M | -18.48M | -56.52M |
| TotalUnusualItems | 0.00 | -3.30M | 0.00 | 2.68M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -3.30M | 0.00 | 2.68M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.06M | -12.59M | -18.25M | -51.65M |
| ReconciledDepreciation | 0.00 | 65.00K | 472.00K | |
| EBITDA | -3.63M | -9.65M | -18.48M | -53.84M |
| EBIT | -3.63M | -9.65M | -18.54M | -54.31M |
| NetInterestIncome | 208.00K | 358.00K | 294.00K | -16.00K |
| InterestExpense | 16.00K | |||
| InterestIncome | 208.00K | 358.00K | 294.00K | |
| NormalizedIncome | -3.06M | -9.29M | -18.25M | -54.33M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.06M | -5.26M | -44.08M | -51.65M |
| TotalExpenses | 5.63M | 9.65M | 18.84M | 57.63M |
| TotalOperatingIncomeAsReported | -3.63M | -12.95M | -18.54M | -55.20M |
| DilutedAverageShares | 2.52M | 2.34M | 2.17M | 1.96M |
| BasicAverageShares | 2.52M | 2.34M | 2.17M | 1.96M |
| DilutedEPS | -1.21 | -2.25 | -20.28 | -26.40 |
| BasicEPS | -1.21 | -2.25 | -20.28 | -26.40 |
| DilutedNIAvailtoComStockholders | -3.06M | -5.26M | -44.08M | -51.65M |
| NetIncomeCommonStockholders | -3.06M | -5.26M | -44.08M | -51.65M |
| NetIncome | -3.06M | -5.26M | -44.08M | -51.65M |
| NetIncomeIncludingNoncontrollingInterests | -3.06M | -5.26M | -44.08M | -51.65M |
| NetIncomeDiscontinuousOperations | 0.00 | 7.33M | -25.83M | |
| NetIncomeContinuousOperations | -3.06M | -12.59M | -18.25M | -51.65M |
| PretaxIncome | -3.06M | -12.59M | -18.25M | -51.65M |
| OtherIncomeExpense | 363.00K | -3.30M | 2.68M | |
| OtherNonOperatingIncomeExpenses | 363.00K | |||
| SpecialIncomeCharges | 0.00 | -3.30M | 0.00 | 2.68M |
| OtherSpecialCharges | -2.68M | |||
| ImpairmentOfCapitalAssets | 0.00 | 3.30M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 208.00K | 358.00K | 294.00K | -16.00K |
| TotalOtherFinanceCost | -294.00K | 16.00K | ||
| InterestExpenseNonOperating | 16.00K | |||
| InterestIncomeNonOperating | 208.00K | 358.00K | 294.00K | |
| OperatingIncome | -3.63M | -9.65M | -18.54M | -54.31M |
| OperatingExpense | 5.63M | 9.65M | 18.84M | 57.63M |
| OtherOperatingExpenses | -1.33M | -622.00K | ||
| ResearchAndDevelopment | 286.00K | 1.51M | 5.98M | 37.64M |
| SellingGeneralAndAdministration | 5.34M | 8.13M | 12.86M | 20.62M |
| GeneralAndAdministrativeExpense | 5.34M | 8.13M | 12.86M | 20.62M |
| OtherGandA | 5.34M | 8.13M | 12.86M | 20.62M |
| TotalRevenue | 2.00M | 0.00 | 297.00K | 3.32M |
| OperatingRevenue | 2.00M | 0.00 | 297.00K | 3.32M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 170.94K | |||
| OrdinarySharesNumber | 2.55M | 2.47M | 2.18M | 2.17M |
| ShareIssued | 2.55M | 2.47M | 2.18M | 2.17M |
| TotalDebt | 0.00 | |||
| TangibleBookValue | 8.85M | 11.29M | 10.45M | 48.25M |
| InvestedCapital | 8.85M | 11.29M | 10.45M | 48.25M |
| WorkingCapital | 3.50M | 5.94M | 7.19M | 44.37M |
| NetTangibleAssets | 8.85M | 11.29M | 10.45M | 48.25M |
| CapitalLeaseObligations | 0.00 | |||
| CommonStockEquity | 8.85M | 11.29M | 10.45M | 48.25M |
| TotalCapitalization | 8.85M | 11.29M | 10.45M | 48.25M |
| TotalEquityGrossMinorityInterest | 8.85M | 11.29M | 10.45M | 48.25M |
| StockholdersEquity | 8.85M | 11.29M | 10.45M | 48.25M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -12.00K | -20.00K | -23.00K |
| OtherEquityAdjustments | -12.00K | -20.00K | -23.00K | |
| RetainedEarnings | -267.49M | -264.42M | -259.15M | -215.08M |
| AdditionalPaidInCapital | 276.34M | 275.72M | 269.63M | 263.35M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 725.00K | 2.09M | 7.63M | 11.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | |||
| LongTermCapitalLeaseObligation | 0.00 | |||
| CurrentLiabilities | 725.00K | 2.09M | 7.63M | 11.09M |
| OtherCurrentLiabilities | 63.00K | 113.00K | 68.00K | 526.00K |
| CurrentCapitalLeaseObligation | 0.00 | |||
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | 1.23M | 1.71M | |
| PayablesAndAccruedExpenses | 662.00K | 1.97M | 6.33M | 8.85M |
| CurrentAccruedExpenses | 272.00K | 775.00K | 3.36M | 7.02M |
| Payables | 390.00K | 1.20M | 2.97M | 1.83M |
| AccountsPayable | 390.00K | 1.20M | 2.97M | 1.83M |
| TotalAssets | 9.57M | 13.37M | 18.08M | 59.33M |
| TotalNonCurrentAssets | 5.35M | 5.35M | 3.26M | 3.87M |
| OtherNonCurrentAssets | 2.04M | 2.41M | ||
| InvestmentsAndAdvances | 5.35M | 5.35M | 0.00 | |
| OtherInvestments | 5.35M | 5.35M | 0.00 | |
| NetPPE | 0.00 | 0.00 | 1.22M | 1.47M |
| AccumulatedDepreciation | -126.00K | -126.00K | -2.18M | -2.20M |
| GrossPPE | 126.00K | 126.00K | 3.40M | 3.67M |
| Leases | 0.00 | |||
| OtherProperties | 1.22M | 1.40M | ||
| MachineryFurnitureEquipment | 126.00K | 126.00K | 2.18M | 2.27M |
| Properties | 0.00 | |||
| CurrentAssets | 4.22M | 8.02M | 14.82M | 55.46M |
| OtherCurrentAssets | 16.00K | 11.00K | 537.00K | 468.00K |
| PrepaidAssets | 421.00K | 442.00K | 805.00K | 928.00K |
| Receivables | 556.00K | 0.00 | 96.00K | 100.00K |
| AccountsReceivable | 556.00K | 0.00 | 96.00K | 100.00K |
| CashCashEquivalentsAndShortTermInvestments | 3.23M | 7.57M | 13.38M | 53.96M |
| CashAndCashEquivalents | 3.23M | 7.57M | 13.38M | 53.96M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.33M | -21.25M | -40.61M | -36.52M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 30.50M | ||
| CapitalExpenditure | -7.00K | |||
| EndCashPosition | 3.23M | 7.57M | 13.38M | 53.96M |
| BeginningCashPosition | 7.57M | 13.38M | 53.96M | 58.23M |
| EffectOfExchangeRateChanges | -6.00K | 8.00K | 3.00K | 4.00K |
| ChangesInCash | -4.33M | -5.82M | -40.58M | -4.28M |
| FinancingCashFlow | 0.00 | 5.02M | 29.00K | 30.79M |
| CashFlowFromContinuingFinancingActivities | 0.00 | 5.02M | 29.00K | 30.79M |
| ProceedsFromStockOptionExercised | 0.00 | 5.02M | 29.00K | 282.00K |
| NetCommonStockIssuance | 0.00 | 30.50M | ||
| CommonStockIssuance | 0.00 | 30.50M | ||
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 0.00 | 10.40M | 0.00 | 1.46M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 10.40M | 0.00 | |
| CashFlowFromContinuingInvestingActivities | 0.00 | 1.46M | ||
| NetPPEPurchaseAndSale | 0.00 | 1.46M | ||
| SaleOfPPE | 0.00 | 1.46M | ||
| PurchaseOfPPE | 0.00 | -7.00K | ||
| OperatingCashFlow | -4.33M | -21.25M | -40.61M | -36.52M |
| CashFromDiscontinuedOperatingActivities | -15.75M | 0.00 | ||
| CashFlowFromContinuingOperatingActivities | -4.33M | -21.25M | -40.61M | -36.52M |
| ChangeInWorkingCapital | -1.54M | -4.60M | -2.85M | 1.41M |
| ChangeInOtherCurrentLiabilities | 0.00 | -1.05M | ||
| ChangeInOtherCurrentAssets | -5.00K | 481.00K | 481.00K | 1.55M |
| ChangeInPayablesAndAccruedExpense | -998.00K | -5.54M | -3.46M | 990.00K |
| ChangeInAccruedExpense | -553.00K | -3.77M | -4.60M | 597.00K |
| ChangeInPayable | -445.00K | -1.77M | 1.14M | 393.00K |
| ChangeInAccountPayable | -445.00K | -1.77M | 1.14M | 393.00K |
| ChangeInPrepaidAssets | 21.00K | 363.00K | 123.00K | -112.00K |
| ChangeInReceivables | -556.00K | 96.00K | 4.00K | 27.00K |
| ChangesInAccountReceivables | -556.00K | 96.00K | 4.00K | 27.00K |
| OtherNonCashItems | -363.00K | -15.75M | 881.00K | |
| StockBasedCompensation | 625.00K | 1.07M | 6.25M | 9.61M |
| AssetImpairmentCharge | 0.00 | 3.30M | 0.00 | |
| DepreciationAmortizationDepletion | 0.00 | 65.00K | 472.00K | |
| DepreciationAndAmortization | 0.00 | 65.00K | 472.00K | |
| OperatingGainsLosses | 2.76M | |||
| GainLossOnSaleOfPPE | 0.00 | 6.32M | ||
| NetIncomeFromContinuingOperations | -3.06M | -5.26M | -44.08M | -51.65M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CYCN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|